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Mads H. Andersen1, Per thor Straten1 and Inge Marie Svane1,3
Further development of adoptive T-cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has the
potential to markedly change the long-term prognosis of patients with metastatic melanoma, and modifications of
the original protocol that can improve its clinical efficacy are highly desirable. In this study, we demonstrated that a
high in vitro tumor reactivity of infusion products was associated with clinical responses upon adoptive transfer. In
addition, we systematically characterized the responses of a series of TIL products to relevant autologous short
term–cultured melanoma cell lines from 12 patients. We provide evidence that antitumor reactivity of both CD8þ
and CD4þ T cells could be enhanced in most TIL products by autologous melanoma sensitization by pretreatment
with low-dose IFN-g. IFN-g selectively enhanced responses to tumor-associated antigens other than melanoma
differentiation antigens. In addition, IFN-g treatment was invariably associated with restored/increased cancer
immunogenicity as demonstrated by upregulation of major histocompatibility complex molecules. These findings
suggest a potential synergism between IFN-g and ACT, and have important implications for clinical development of
combination strategies for the treatment of metastatic melanoma.
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INTRODUCTION
Despite recent advances in the field, the prognosis of patients
with AJCC (American Joint Committee on Cancer) stage IV
melanoma remains to be very poor with a median survival
below 12 months (Balch et al., 2009). Adoptive T-cell therapy
(ACT) with tumor-infiltrating lymphocytes (TILs) represents one
of the most promising therapies in clinical development, with
superior efficacy demonstrated in independent clinical trials
carried out at three different institutions (Dudley et al., 2008;
Besser et al., 2010; Joseph et al., 2011). This immune-based
therapy consists of the isolation, in vitro activation, and
expansion of tumor-derived T cells that are reinfused into the
patient in combination with IL-2 after chemotherapy induced
lymphodepletion (Dudley et al., 2008). Upon infusion, effective
TILs should be able to traffic to the tumor site, recognize
antigens expressed in association with major histocompatibility
complex (MHC) molecules by melanoma cells, and exert
cytotoxic effector functions. All these steps are fundamental
for efficient tumor destruction and clinical response to
treatment. Theoretically, the possibility to improve clinical
efficacy of ACT relies mostly on the improvement of the
quality of T-cell products for infusion, or on effective
manipulation of the host increasing the capacity of TILs to
persist, migrate to the tumor site, and recognize tumor cells.
During the process of tumorigenesis and tumor progression,
under the pressure of a competent immune system trans-
formed melanocytes develop strategies to escape adaptive
immune responses through changes in MHC molecule expres-
sion and induction of antigen-processing machinery defects.
These changes can in turn negatively affect the course of the
disease (van Duinen et al., 1988; Kageshita et al., 1999;
Anichini et al., 2006) and limit the effectiveness of immune-
based therapies (Aptsiauri et al., 2008). Potent immune-
modulatory molecules such as IFN-g possess the capacity to
increase MHC-dependent antigen presentation in a variety of
cell populations including transformed melanocytes both
in vitro (Seliger et al., 2008) and in vivo (Propper et al.,
2003). Previous studies have shown that IFN-g differently
modulates the sensitivity of melanoma cells to cytolytic T-cell
clones recognizing distinct antigens, and does not increase
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melanoma killing by clones specific for differentiation
antigens (Kirkin et al., 1996). However, we have recently
shown that clinically relevant TIL products contain a variety of
T cells specific not only for differentiation antigens but also for
cancer-testis, mutation, and overexpressed tumor antigens
(Andersen et al., 2012; Junker et al., 2012). Altogether, these
data suggest that T-cell responses of TIL products might be
increased with immuno-sensitizing agents.
In this report, we first demonstrated that in vitro antitumor
reactivity of infusion products was associated with the like-
lihood to achieve a clinical response upon adoptive transfer.
Next, we systematically characterized the responses of a series
of TILs to relevant autologous short term–cultured melanoma
cell lines treated with or without low-dose IFN-g. Most TIL
products generated with current clinical protocols contained a
fraction of either CD8þ cytotoxic T lymphocytes (CTLs) or
CD4þ T helper 1 tumor-specific TILs whose responses against
autologous tumors could be significantly enhanced by mela-
noma sensitization with IFN-g, augmenting the overall reac-
tivity of the cell products.
RESULTS
Association of absolute number of tumor-reactive T cells and
clinical response
We first analyzed the number of tumor-reactive CD8þ T cells
contained in TIL products for patient infusion in a pilot ACT
clinical trial initiated at our institution (Clinicaltrials.gov Iden-
tifier: NCT00937625). Infusion products from four patients
were tested against autologous melanoma cell lines, whereas
from four additional patients an autologous cell line was not
available. As previous studies have shown that allogeneic cell
lines are suitable for the analysis of TIL reactivity (Carlsson
et al., 2008), for this last group of patients the reactivity of
infusion products was tested against a panel of four to eight
HLA-A-matched allogeneic melanoma cell lines.
We calculated the total absolute numbers of in vitro
tumor-reactive CD8þ T cells from the absolute number of
CD8þ T cells infused and the percentage of tumor-reactive
CD8þ T cells in the infusion products.
Previously, the analysis of infusion products for ACT from
the first six patients treated in this trial had suggested a
possible association between tumor reactivity of TILs and
achievement of a clinical response (Ellebæk et al., 2012). An
updated analysis from eight patients evaluated to date
confirmed the association of clinical response and higher
absolute numbers of tumor-reactive CD8þ T cells infused
(Figure 1). These data point out the importance of tumor
recognition as a prerequisite for clinical efficacy, although
further confirmation in a larger series of patients is needed.
Generation of autologous melanoma and TIL cultures
Tumor specimens obtained from subcutaneous or lymph
node metastasis of 29 patients with melanoma AJCC stage III
or IV were received for processing. From 12 patients (41%),
we were able to generate a short-term melanoma cell line
and at least one clinical-grade TIL culture from the same
metastatic lesion. The mean age of these 12 patients at time
of tissue acquisition was 52±21 years. Six specimens were
from male patients, and six were from female patients. Four
patients were HLA-A2þ .
MHC expression by short term–cultured melanoma cell lines
Previous studies have demonstrated a close correlation
between melanoma lesions and corresponding expression of
antigen-processing machinery components and class I and II
MHC molecules on short term–cultured cell lines (Anichini
et al., 2006). Although all cell lines generated in our study
expressed class I MHC molecules, their level of expression
was not uniform and very low in one case (patient 3).
Importantly, increased expression was achieved in all the
cell lines by treatment with low-dose IFN-g, although the
increase was not uniform (mean fold increase was 4.4±2.6,
Supplementary Figure S1 online).
Six out of twelve (50%) melanoma cell lines constitutively
expressed class II MHC molecules. Treatment with IFN-g led
to increased expression of MHC II in 11 out of 12 (92%)
melanoma cell lines (mean fold increase for constitutively
MHC IIþ cell lines was 21.3±12.5, Supplementary Figure S1
online). One cell line (from patient 4) did not express class II
MHC neither before nor after IFN-g treatment (Supplementary
Figure S1 online).
In vitro antitumor activity of CD8þ T cells in clinical-grade TILs
The antitumor activity of CD8þ T cells expanded from TILs
was evaluated by defining the frequency of cells expressing at
least the two type 1 cytokines tumor necrosis factor-a and
IFN-g (double positive (DP)) or these two cytokines and
CD107a (triple positive) upon stimulation with autologous
cancer cells treated with or without low-dose IFN-g. Stimula-
tion with untreated target cells defined the ‘‘constitutive’’
response of TILs.
Antitumor responses were detected in all the TILs analyzed,
with frequency of responses varying greatly between differ-
ent pairs (mean DP cells: 5.5±10.5%, range 0.27–37.6%
of CD8þ TILs) (Figure 2a and Table 1). Interestingly,
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Figure 1. Association of clinical response and absolute number of in vitro
tumor-reactive CD8þ T cells in infusion products for adoptive T-cell therapy
(ACT). Infusion products were tested for reactivity against autologous
melanoma cell lines (indicated with the arrow), or, when an autologous cell
line was not available, against a panel of four to eight HLA-A-matched
allogeneic melanoma cell lines (only the highest reactivity is shown). Data
show that clinical response is associated with a higher absolute number of
infused in vitro tumor-reactive CD8þ tumor-infiltrating lymphocytes. CR/PR,
complete response or partial response; SD/PD, stable disease or progressive
disease.
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coincubation with target cells pretreated with IFN-g led to an
increased frequency of DP cells in 10 out of 12 pairs, with a
mean increase of 4.9±4.3% (range 0.2–12.9%) (Figure 2 and
Table 1). Thus, in TIL products from most patients, pretreatment
of target cells with IFN-g unleashed the responses of a large
quantity of cells that were not able to recognize tumor/exert
effector functions constitutively. On the other hand, in 2 out of
12 pairs, the response was slightly reduced in frequency (mean
decrease 0.23±0.02%, range 0.21–0.24%) (Table 1). A similar
trend was observed for production of CD107a, with increased
frequency of triple positive cells in 9 out of 12 (mean triple
positive cells in CD8þ TILs: 2.1±5.6 vs. 2.9±5.6%, respec-
tively, for untreated cells or cells treated with IFN-g)
(Supplementary Figure S4 online), confirming the multifunc-
tionality of these antitumor CD8þ T cells. It is of particular
interest that responses towards a tumor cell line that showed
very low constitutive expression of class I MHC increased from
almost undetectable to high levels (patient 3, Figure 2b lower
panel and Table 1). On the contrary, a small increase of class
I MHC expression was observed in the two tumor cell lines
in which the autologous TILs failed to increase the response
(patient 9 and 10, Table 1 and Supplementary Figure S1
online).
IFN-c-induced changes of tumor recognition by CD8þ TILs
specific for defined antigens
To characterize the antigens responsible for the observed
increased tumor recognition, TILs from three different patients
displaying a high frequency of CD8þ T cells specific for
defined tumor-associated antigens were further tested in
cocultures with autologous tumor cells with or without low-
dose IFN-g followed by combined intracellular cytokine- and
fluorochrome-conjugated peptide–MHC multimer staining.
Recognition of autologous tumor cells by MART-1-specific
CD8þ TILs (patient 8) was not increased, despite simulta-
neous improved recognition by CD8þ T cells specific for
undefined antigens (Figure 3a). However, autologous tumor
recognition by MAGE-A1-specific CD8þ TILs (patient 2) was
significantly enhanced in parallel to an enhanced recognition
of autologous tumor by the remaining CD8þ T-cell popula-
tion (Figure 3b). Finally, neither recognition of autologous
tumor cells by TAG-specific CD8þ TILs (patient 10) nor
recognition by the remaining CD8þ TILs in the same culture
was increased (Figure 3c), probably reflecting specific features
of this tumor cell line leading to IFN-g insensitivity despite
MHC upregulation.
To further scrutinize the effects of IFN-g treatment on tumor
recognition by CD8þ T cells specific for tumor-associated
antigens, TIL cultures enriched with CD8þ T cells specific for
defined tumor-associated antigens were tested against auto-
logous or allogeneic melanoma cells. Tumor recognition of
MART-1 (against four allogeneic cell lines)- or gp100 (against
one allogeneic cell line)-specific T cells, used as a model of
melanoma differentiation antigens, was not increased follow-
ing IFN-g treatment in any case (Supplementary Figure S2
online). In addition, and as previously observed, recognition of
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Figure 2. IFN-g increased autologous tumor recognition by CD8þ tumor-infiltrating lymphocytes (TILs). TILs were stimulated with autologous target melanoma
cells as described in Materials and Methods. (a) Figure shows the frequency of cytokine-producing CD8þ TILs upon stimulation with autologous tumors in the left
panel, and the difference for each sample (IFN-g treated minus control) in the right panel. (b) Histograms and plots show, respectively, class I MHC expression and
cytokine production by CD8þ TILs. Two TIL/autologous tumor pairs are depicted, representing an increase of tumor recognition associated with significant
upregulation of class I MHC (upper panel) in a constitutively MHC Iþ tumor and (lower panel) in a tumor with very low MHC I expression. Plots are gated on live
CD8þ TILs. Dotted gray line, isotype. Solid gray line, untreated cell line. Solid black line, IFN-g-treated cell line. CI, confidence interval; Pt., patient.
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autologous tumor by TAG-specific T cells (from patient 10)
was not increased (Supplementary Figure S3a online).
However, recognition of melanoma cells of patient 12 by
AIM-2-specific T cells was improved with IFN-g pretreatment
(Supplementary Figure S3b online).
In vitro antitumor activity of CD4þ T cells in clinical-grade TILs
The antitumor activity of CD4þ T cells expanded from TILs
was evaluated by defining the frequency of DP cells in the
same setting described earlier. A positive constitutive anti-
tumor CD4þ T helper 1 response was detected in 4 out of 12
TILs analyzed (mean number of DP in responding cultures:
1.5±1.3%, range 0.08–3.3% of CD4þ TILs) (Figure 4 and
Table 1). As expected, constitutive responses were detected
only in pairs with MHC IIþ tumors (Table 1 and
Supplementary Figure S1 online). IFN-g pretreatment induced
an increase in frequency of CD4þ DP TILs in 6 out 12 pairs,
with a mean increase of 4.0±7.0% (range 0.21±17.9%). It is
noteworthy that four of these pairs displayed responses at
baseline (patient 1, 2, 5 and 11) and two additional borderline
responses (patient 8 and 9) (Figure 4 and Table 1). All the
increased responses matched with increased expression of
class II MHC (Supplementary Figure S1 online). As expected,
we did not detect any expression of CD107a by CD4þT cells
(see representative CD8 population in Supplementary Figure
S4b online).
Two pairs selected for high frequency of CD4þ DP TILs
(patients 1 and 5, Table 1) were tested for IL-4 production by
FACS along with tumor necrosis factor-a and IFN-g. Produc-
tion of IL-4 could not be detected under these conditions,
confirming the T helper 1 profile of these tumor-specific cells
(data not shown).
Expression of immune-suppressive molecules by melanoma cells
It was previously shown that IFN-g may favor immune escape
by tumor cells (Zaidi and Merlino, 2011). Therefore, we
checked whether alongside increased/restored expression of
molecules associated with increased immune recognition, the
same dose of IFN-g may in turn also increase the expression of
well-known immune-suppressive molecules such as
indoleamine 2,3-dioxygenase (IDO) (Singer et al., 2011) and
programmed death cell ligand 1 (PD-L1) (Blank and
Mackensen, 2007). Ten short term–cultured cell lines were
available for analysis. Constitutive expression of IDO was
detected in 2/10 cell lines, whereas PD-L1 was detected in 10/
10 cell lines although at different levels. Strikingly, both IDO
Table 1. Summary of antitumor responses of TILs
stimulated with autologous tumor cells treated IFN-g
(þ IFN-g) or left untreated ( IFN-g)
CD8þ TILs CD4þ TILs
 IFN-c þ IFN-c  IFN-c þ IFN-c
Patient number
1a 1.45±1.80 4.40±5.33 3.25±1.64 21.19±13.34
2a 8.09±8.06 16.67±16.62 1.50±1.57 2.12±2.05
3a 0.27±0.19 8.20±6.06 NR BR
4 37.62 44.31 BR BR
5 2.54 3.84 1.12 5.56
6 0.26 0.60 NR BR
7 0.45 0.65 NR NR
8 3.80 16.66 BR 0.85
9 0.29 0.08 BR 0.33
10a 2.61±3.09 2.37±1.86 BR BR
11 7.98 14.40 0.08 0.29
12 0.91 2.31 NR NR
Mean 5.52 9.57 0.50 2.53
SD 10.49 12.62 1.00 6.09
Paired t-test 0.008
Wilcoxon test 0.031
Abbreviations: BR, borderline response; NR, no response; TILs, tumor-
infiltrating lymphocytes.
Responses are expressed as percentage of TILs co-expressing TNF-a and
IFN-g.
Limit of sensitivity was set at 0.01.
aMore than one independent TIL culture were analyzed; mean±SD is
shown.
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Figure 3. Effects of IFN-g on autologous tumor recognition by CD8þ tumor-
infiltrating lymphocytes (TILs) specific for defined tumor-associated antigens.
TILs were stimulated with autologous target melanoma cells as described in
Materials and Methods. Plots show the frequency of cytokine-producing CD8þ
TILs of defined specificity (gray dots) or of undefined specificity (black dots)
upon stimulation with autologous tumor cells. (a) Reduced recognition by
MART-1-specific CD8þ TILs with concomitant increased recognition by
CD8þ TILs of undefined specificity. (b) Increased recognition by MAGE-A1-
specific CD8þ TILs and concomitant increased recognition by CD8þ
TILs of undefined specificity. (c) Reduced recognition by TAG-specific
CD8þ TILs with stable/reduced recognition by CD8þ TILs of undefined
specificity. Pt., patient.
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and PD-L1 were increased in 10/10 cell lines upon treatment
with IFN-g (Supplementary Figure S5 online). These results
confirm the potentially harmful effects of IFN-g reported
previously, and highlight its powerful ability to strongly
influence simultaneously several cellular pathways connected
to immune regulation.
Direct effects of IFN-c on short term–cultured melanoma cell
cultures
Previous reports have shown that IFN-g treatment, especially
when delivered at doses exceeding 1000 IU ml 1, might
directly influence melanoma cell growth by inhibition of
proliferation and induction of cell cycle arrest followed by a
marginal induction of apoptosis (Kortylewski et al., 2004). To
check whether the applied low dose of 100 IU ml1 IFN-g,
able to increase tumor cell recognition, may also influence
growth and viability of tumor cells, nine short term–cultured
melanoma cell lines were exposed to this dose for 72 hours.
Significant growth inhibition was observed in 5/9 cell lines,
with cell loss observed in one case (cell line from patient 3)
(Supplementary Figure S6a online). An increased frequency of
apoptotic cells after 24 hours of exposure to the drug (higher
percentage of subG events) was observed in only one cell line
(from patient 3) (data not shown). Under the same experi-
mental conditions, the cell cycle distribution was not signifi-
cantly influenced (Supplementary Figure S6b online). Thus,
we concluded that short term–cultured melanoma cells
exposed to 100 IU ml 1 may directly affect tumor cell growth,
without significant induction of apoptosis in most cases.
DISCUSSION
Adoptive transfer of adequate number of TILs following
lymphodepletion has the potential to markedly change the
long-term prognosis of patients with metastatic melanoma
(Rosenberg et al., 2011). Our results indicate that reactivity
against melanoma cells is critical to achieve clinical
responses. Therefore, the development of strategies to
improve tumor recognition and thereby the efficacy of TIL
treatment further is highly warranted.
TIL products for infusion are composed of a heterogeneous
population of CD4þ and CD8þ T lymphocytes derived from
natural tumor-associated T cells that are enriched with in vitro
tumor-reactive T-cell clones (Donia et al., 2011). We have
previously shown that 0.5–50% of the total CD8þ TIL
population is tumor-reactive in vitro (Donia et al., 2011),
and that a fraction of CD8þ TILs (about 1–5% of the total
population) may be specific for nontumor-related microbial
pathogens (Andersen et al., 2012). Thus, the frequency of
tumor-reactive CD8þ T cells appeared to be rather low.
However, naturally generated T cells specific for tumor
antigens, such as those contained in TIL products, have a
selective disadvantage compared with pathogen-specific
T cells, because anticancer T cells usually express T-cell
receptors of lower affinity/avidity for their relevant ligands
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Figure 4. IFN-g increased autologous tumor recognition by CD4þ tumor-infiltrating lymphocytes (TILs). TILs were stimulated with autologous target melanoma
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(Dunn et al., 2004). A close relationship exists between T-cell
functional avidity and target cell recognition; thus, T cells with
lower avidity require higher density of peptide-MHC on
targets to produce meaningful responses (Alexander-Miller
et al., 1996; Zeh et al., 1999; Schmid et al., 2010). In this
way, the levels of specific peptide–MHC I complexes on the
surface of tumor cells can influence the susceptibility to CTL
recognition. IFN-g may increase the density of peptide–MHC
complexes because of its properties to enhance antigen
processing and expression of MHC molecules (Weidanz
et al., 2006). In line with this, results of this report revealed
that a fraction of previously uncharacterized/unresponsive
CD8þ TILs are indeed specific for autologous melanoma
cells. Presumably, IFN-g pretreatment may restore these
responses by increasing the density of peptide–MHC com-
plexes on target cells, thereby unleashing responses of TILs
with lower-affinity/-avidity T-cell receptors.
However our results showed, additionally, that IFN-g
selectively enhanced responses to tumor-associated antigens
other than melanoma differentiation antigens. We indeed
provided direct demonstration that reactivity of CD8þ TILs
specific for cancer-testis (such as MAGE-A1) and tumor over-
expressed antigens (such as AIM-2) can be improved with this
strategy. To this end, it is likely that a fraction of the tumor-
specific CD8þ TILs specific for uncharacterized antigens
whose responses are increased by IFN-g were specific for
antigens derived from the expression of mutant genes.
In light of our data, an in vivo sensitization step of the
cancer cells could increase clinically significant antitumor
response upon adoptive transfer of cancer-specific CD8þ TILs
especially for those patients bearing tumors with strongly
impaired class I MHC expression. However, these findings
limit the potential benefit of IFN-g to those settings in which
T cells specific for tumor-associated antigens other than
differentiation antigens have an important role.
Previous studies have shown that TIL products generated
from patients with melanoma display tumor-specific activity in
about 80% of cases (Dudley et al., 2003). However, in this
report, we showed that all the TIL products generated
contained tumor-specific CD8þ T cells. This is probably due
to the higher sensitivity of our method of analysis, which used
staining of two intracellular cytokines after stimulation with
autologous tumor cells.
CD4þ TILs in melanoma have so far not been extensively
characterized, and as a consequence very little is known of
CD4þ T cells among clinical-grade TILs and their ability to
exert tumor-specific effector functions, despite the fact that it
was shown that these cells can directly mediate (Hunder et al.,
2008; Besser et al., 2009) or significantly contribute (Robbins
et al., 2002) to the achievement of clinical responses.
CD4þ T cells recognize antigens presented in association
with class II MHC molecules, whose expression is mostly
restricted to professional antigen-presenting cells, which
process exogenous tumor antigens and display them on their
surface (Vyas et al., 2008). However, a significant fraction
(over 40%) of human melanoma cells constitutively express
class II MHC molecules (Mendez et al., 2009), and class II
MHC-restricted peptides can also be processed endogenously
via autophagy and be displayed on the surface of the tumor
cells, allowing direct recognition of tumor antigens (Nuchtern
et al., 1990; Muranski and Restifo, 2009). Our data point
out that clinical-grade TIL cultures may actually contain a
significant fraction of tumor-specific T helper 1-polarized
CD4þ T cells, and a combination of ACT with admini-
stration of IFN-g could potentially increase clinical responses
at least in part based on a more proper exploitation of
the antitumor functionality of CD4þ T cells contained
in unselected cellular products. However, it is less common
to find CD4þ than CD8þ tumor-reactive TILs, as they were
found in 50 vs. 100% of patients, with a mean frequency of
approximately 3 vs. 10%. These findings are consistent with
results from larger cohorts of patients treated with ACT,
showing an increased likelihood of clinical response in
patients infused with higher numbers of CD8þ T cells
(Prieto et al., 2010; Itzhaki et al., 2011; Kllgaard et al.,
2012), leading to the initiation of a trial with CD8þ -enriched
TILs (Dudley et al., 2010). On the basis of our findings, higher
absolute numbers of CD8þ TILs could translate into higher
numbers of tumor-reactive cells.
Currently, IFN-g is considered a double-edged sword
because of its ability to increase, as well as to reduce, tumor
cell susceptibility to immune-mediated cytotoxicity depending
on the setting considered (Zaidi and Merlino, 2011). Our
results confirmed that a short-term low-dose IFN-g exposure
of cancer cells is able to induce upregulation of molecules
associated with increased immune recognition, such as class I
and II MHC molecules. But most importantly, we provided
direct evidence that this increased immunogenicity could be
associated with increased anticancer responses by either
CD8þ or CD4þ T cells naturally present in ACT products.
Simultaneously, the expression of the immune-suppressive
molecules IDO and PD-L1 was also upregulated in all
samples. Therefore, although we cannot rule out the possibi-
lity of detrimental effects of IFN-g treatment in other settings,
the data presented clearly show that in most cases the change
of immune-stimulating/immune-suppressive factors induced by
short term exposure of cancer cells to low-dose IFN-g achieves,
as a net effect, an increased immune recognition.
Indeed, although previous clinical experience with IFN-g
monotherapy for melanoma has been largely disappointing
(Maluish et al., 1988; Kirkwood et al., 1990; Schiller et al.,
1996; Propper et al., 2003), these results suggest a potential
synergism between IFN-g and ACT. Notably, IFN-g (IFN-1b,
marketed as follows: Actimmune, Intermune, Brisbane, CA,
USA or Imukin, Boehringer Ingelheim, Ingelheim am Rhein,
Germany) was used safely for over 10 years in the treatment of
chronic granulomatous disease and severe, malignant
osteopetrosis. Previous clinical trials in melanoma have safely
used much higher doses of IFN-g, up to 3000 mcg m2 per day
(Kirkwood et al., 1990). Therefore, the dose of 100 IU ml 1
used in our study was chosen as it can most likely be achieved
in plasma without serious adverse effects. To this end, a clinical
trial with infusion of autologous NY-ESO-1-specific CD8þ T
cells in combination with low-dose weekly IFN-g for patients
with metastatic soft tissue sarcoma was recently initiated
(Clinicaltrials.gov Identifier: NCT 01477021).
M Donia et al.
Improving Adoptive T-Cell Therapy with IFN-g
550 Journal of Investigative Dermatology (2013), Volume 133
A synergistic activity with IFN-g may not be limited to the
combination with ACT. New immune-modulating strategies
such as CTL antigen-4 (CTLA-4) or PD-1/PD-L1 blockade work
by increasing adaptive immune effector mechanisms. Previous
studies have shown that the transfer of tumor-reactive naive
CD4þ T cells into lymphopenic recipients in association with
CTLA-4 blockade was able to induce powerful regression of
mouse melanoma, and tumor rejection appeared to be highly
dependent on CD4þ -derived IFN-g that induced class II MHC
expression on cancer cells (Quezada et al., 2010). To this end,
the demonstration that CD4þ tumor-specific TILs are naturally
infiltrating tumors in about 50% of patients with metastatic
melanoma warrant additional studies on a combination
treatment with CTLA-4 antagonists and exogenously admini-
stered class II MHC upregulating agents such as IFN-g.
In conclusion, strategies to increase tumor cell recognition
in vivo may increase the success rate of ACT and other
immune-based therapies for the benefit of patients with
metastatic melanoma. Combination strategies represent the
next frontier of cancer immunotherapy. The addition of IFN-g,
or IFN-g-inducing molecules such as IL-12 (Daud et al., 2008),
to current regimens for host preconditioning may potentially
increase the response rate to ACT by augmenting tumor
reactivity of T cells in the infusion products, which we
demonstrated here to be a critical factor for the achievement
of a clinical response.
Furthermore, it may be important to rescue drugs that failed
when used as single agents such as IFN-g because of their
potential synergism with more effective treatments (Ascierto
and Marincola, 2011). The potential application of these
findings to other tumor histologies broadens the possibilities
of these combinations. Therefore, additional studies on the
possibility of a sequential combination of IFN-g treatment and
ACT for the treatments of patients with metastatic melanoma
are highly warranted.
MATERIALS AND METHODS
Clinical trial and tumor specimens
All the procedures were approved by the Scientific Ethics Committee
for the Capital Region of Denmark. Written informed consent was
obtained from patients before any procedure according to the
Declaration of Helsinki. Response evaluation in the ACT clinical trial
(Clinicaltrials.gov Identifier: NCT 00937625) was carried out accord-
ing to standard criteria for response evaluation in solid tumors
(RECIST), as described elsewhere (Ellebæk et al., 2012).
Tumor specimens of at least 1 cm3 were obtained from patients
with melanoma stage III or IV undergoing standard-of-care surgical
procedures or specimen collection for enrolment in a clinical trial
(Clinicaltrials.gov Identifier: NCT 00937625).
Antitumor activity of TILs and FACS analysis of melanoma cells
For simultaneous CD107a and intracellular cytokine analysis, TILs
were cultured for 5 hours at 37 1C with 5% CO2 in air in the presence
or absence (negative control) of autologous cancer cells or four to
eight HLA-A-matched allogeneic melanoma cell lines (only for
infusion products from the clinical trial) at an effector/target (E:T)
ratio of 3:1, as previously described (Donia et al., 2011). Matched cell
lines had at least one HLA-A allele in common with the relevant TILs.
Autologous cancer cells used as target were pretreated with
100 IU ml 1 IFN-g for 72 hours or were left untreated. For direct
analysis of melanoma cells, after 72 hours of incubation with or
without 100 IU ml 1 of IFN-g, adherent cells were collected by
standard trypsinization, washed twice with cold PBS, and stained
with anti-HLA or PD-L1 antibodies. Additional controls with isotype-
matched antibodies were set up to define background staining.
Cells were acquired using a BD FACSCanto II flow cytometer (BD,
Albertslund, Denmark). At least 200,000 live TILs or 10,000 live
melanoma cells were acquired. Analysis was performed with the BD
FACSDiva Software or FlowJo (Tree Star, Ashland, OR).
Criteria to define a positive antitumor response were as follows: at
least twice the frequency of the background and at least 50 positive
events; otherwise, at least 10 times the background. When the frequency
was between twice and 10 times the background but less than 50
positive events were acquired, the response was defined as ‘‘border-
line’’. D’Agostino-Pearson normality test was performed to check for
normal distribution of the values. Results were compared between
different groups with two-tailed Mann–Whitney test (comparison
between responders/nonresponders of the clinical trial), or with
two-tailed t-test for paired data and Wilcoxon-matched pairs test
(comparison with IFN-g treated or untreated), respectively, for normally
or non-normally distributed sets of data. Statistical Analysis was
performed with GraphPad Prism 5 (GraphPad Software, La Jolla, CA).
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